Ironwood Pharmaceuticals (IRWD) 13.11 $IRWD
Biotech Equities Technical Momentum -- Research on Ironwood Pharma, Neurocrine Biosciences, Rigel Pharma, and Seattle Genetics
PR Newswire - Thu May 08, 8:10AM CDT
The trading session on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,518.54, up 0.72% and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the day 0.56% higher at 1,878.21. During the trading session eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.23% higher at 668.01, and the index has advanced 2.50% in the previous three months. Investor-Edge has initiated coverage on the following equities: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) and Seattle Genetics Inc. (NASDAQ: SGEN). Free technical research on IRWD, NBIX, RIGL and SGEN can be downloaded upon signing up at:
Irritable Bowel Syndrome - Pipeline Review, H1 2014: 29 Companies and 37 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqsgh4/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Alba Therapeutics Corporation - AlbireoPharma - Alfa Wassermann S.p.A - AltheRx Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Dainippon Sumitomo Pharma Co., Ltd. - Dong-A Socio Holdings Co Ltd - Drais Pharmaceuticals, Inc. - Furiex Pharmaceuticals, Inc. - GIcare Pharma Inc - Hanmi Pharmaceuticals, Co. Ltd. - ImmusanT, Inc. - Ironwood Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - MicroDose Therapeutx, Inc. - Ono Pharmaceutical Co., Ltd. - ProMetic Life Sciences Inc. - Protagonist Therapeutics Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - SK Chemicals Co., Ltd. - Synergy Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Takeda Pharmaceutical Company Limited - Tioga Pharmaceuticals, Inc. - X-BODY BioSciences, Inc. - Yuhan Corporation Drug Profiles: - ramosetron - ibodutant - linaclotide - rifaximin - asimadoline - dexloxiglumide - eluxadoline - rifaximin - tenapanor - linaclotide - plecanatide - solabegron hydrochloride - elobixibat - ONO-2952 - LX-1033 - ASP-7147 - (mosapride Bacillus subtilis Streptococcas feacium) - DSP-6952 - SKI-3246 - SYN-010 - linaclotide - larazotide acetate - DA-6886 - YH-12852 - mexiletine hydrochloride - MDT-006 - RQ-00202730 - PBI-1737 - RQ-00310941 - GIC-1001 For more information visit http://www.researchandmarkets.com/research/tq...able_bowel
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2014 Healthcare Conference
Business Wire - Wed May 07, 7:30AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Bank of America Merrill Lynch 2014 Healthcare Conference on Tuesday, May 13, 2014 at 3:40 p.m. Pacific Time/6:40 p.m. Eastern Time at the Encore at the Wynn in Las Vegas, NV.
Positive Data, Financial Results, and Drug Development Programs - Analyst Notes on Novavax, Ironwood, XOMA, Luminex and Amicus
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Novavax, Inc. (NASDAQ: NVAX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), XOMA Corporation (NASDAQ: XOMA), Luminex Corporation (NASDAQ: LMNX) and Amicus Therapeutics, Inc. (NASDAQ: FOLD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1940-100free.
Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week(R) 2014
Business Wire - Thu May 01, 7:31AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today they will present linaclotide-related data during Digestive Disease Week(R) 2014 in Chicago, May 3 through May 6, 2014. The data will be presented through the following poster presentations:
Ironwood Up as Loss Narrows, Linzess Shines - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:45PM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) reported a loss of 38 cents per share in the first quarter of 2014.
Why Ironwood Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 1:11PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Ironwood Pharmaceuticals , a...
Why Ironwood Pharmaceuticals (IRWD) Stock Is Soaring Today
at The Street - Tue Apr 29, 9:33AM CDT
Ironwood Pharmaceuticals (IRWD) is up double digits after beating analysts first quarter revenue estimates by 71%
Upcoming Earnings Release Dates -- Research on HudsonCity Bancorp, 3D Systems, Ironwood Pharma, and Archer-Daniels-Midland
PR Newswire - Tue Apr 29, 7:50AM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Hudson City Bancorp Inc. (NASDAQ: HCBK), 3D Systems Corp. (NYSE: DDD), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) and Archer-Daniels-Midland Co. (NYSE: ADM). Full earnings notes on HCBK, DDD, IRWD and ADM can be downloaded upon signing up at:
Ironwood Pharmaceuticals Provides First Quarter 2014 Investor Update
Business Wire - Tue Apr 29, 6:05AM CDT
--- Multi-channel Direct-to-Consumer awareness campaign launched -
Valeant Eyes Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:40PM CDT
Shares of Allergan (AGN) gained 15.2% after Valeant Pharmaceuticals International, Inc. (VRX) and Pershing Square Capital Management, L.P made a formal proposal to acquire the former.
Upcoming Conference Calls, Commencement of Shipments, Stock Price Movements, Awareness Campaigns, and Acquisitions - Analyst Notes on Incyte, Impax, ANI, Ironwood and Aastrom
PR Newswire - Thu Apr 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), Impax Laboratories Inc. (NASDAQ: IPXL), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) and Aastrom Biosciences, Inc. (NASDAQ: ASTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1519-100free.
Why Ironwood Pharmaceuticals (IRWD) is Poised to Beat Earnings Estimates (Again) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 7:56AM CDT
Recent estimates have been moving higher for Ironwood Pharmaceuticals which is a great sign of a coming beat.
Ironwood Pharmaceuticals and Forest Laboratories announce new LINZESS campaign
M2 - Fri Apr 11, 7:26AM CDT
US-based medicinal company Ironwood Pharmaceuticals (NasdaqGS:IRWD) and US-based Forest Laboratories (NYSE:FRX) launched on Thursday a new direct-to-consumer (DTC) patient awareness campaign for LINZESS (linaclotide) for treating adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Ironwood and Forest Launch New Direct-to-Consumer Awareness Campaign For LINZESS(R)
Business Wire - Thu Apr 10, 7:30AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today that they have commenced a new direct-to-consumer (DTC) patient awareness campaign for LINZESS(R) (linaclotide), a once-daily treatment for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). The campaign aims to help adults suffering from IBS-C or CIC recognize the symptoms of these disorders, describe their symptoms to their doctor, and ask their doctor about LINZESS to help proactively manage their disease. The television portion of the campaign premiered last night on ABC.
Ironwood Pharmaceuticals to Host First Quarter 2014 Investor Update Call
Business Wire - Tue Apr 08, 6:00AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2014 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, April 29, 2014. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 3733415. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
Ironwood Initiates GERD Study, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:25PM CDT
Ironwood Pharmaceuticals announced the initiation of a phase IIa study on its gastroesophageal reflux disease candidate, IW-3718.
Use Options For A Chance To Buy IRWD At A 31% Discount
at The Street - Wed Mar 19, 10:42AM CDT
Looking back to 36 days ago, Ironwood Pharmaceuticals Inc. priced a 13,725,500 share secondary stock offering at $12.75 per share.
Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease
Business Wire - Tue Mar 18, 7:00AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in its Phase IIa clinical study of its investigational compound IW-3718 in patients suffering from gastroesophageal reflux disease (GERD) who have not responded adequately to treatment with a proton pump inhibitor (PPI). Data are expected in the first half of 2015.
Biotech Equities Technical Momentum -- Research on Ironwood Pharma, Neurocrine Biosciences, Rigel Pharma, and Seattle Genetics
PR Newswire - Thu May 08, 8:10AM CDT
The trading session on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,518.54, up 0.72% and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the day 0.56% higher at 1,878.21. During the trading session eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.23% higher at 668.01, and the index has advanced 2.50% in the previous three months. Investor-Edge has initiated coverage on the following equities: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) and Seattle Genetics Inc. (NASDAQ: SGEN). Free technical research on IRWD, NBIX, RIGL and SGEN can be downloaded upon signing up at:
Irritable Bowel Syndrome - Pipeline Review, H1 2014: 29 Companies and 37 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/tqsgh4/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - A. Menarini Industrie Farmaceutiche Riunite Srl - Alba Therapeutics Corporation - AlbireoPharma - Alfa Wassermann S.p.A - AltheRx Pharmaceuticals, Inc. - Astellas Pharma Inc. - AstraZeneca PLC - Dainippon Sumitomo Pharma Co., Ltd. - Dong-A Socio Holdings Co Ltd - Drais Pharmaceuticals, Inc. - Furiex Pharmaceuticals, Inc. - GIcare Pharma Inc - Hanmi Pharmaceuticals, Co. Ltd. - ImmusanT, Inc. - Ironwood Pharmaceuticals, Inc. - Lexicon Pharmaceuticals, Inc. - MicroDose Therapeutx, Inc. - Ono Pharmaceutical Co., Ltd. - ProMetic Life Sciences Inc. - Protagonist Therapeutics Inc. - RaQualia Pharma Inc. - Rottapharm|Madaus - SK Chemicals Co., Ltd. - Synergy Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Takeda Pharmaceutical Company Limited - Tioga Pharmaceuticals, Inc. - X-BODY BioSciences, Inc. - Yuhan Corporation Drug Profiles: - ramosetron - ibodutant - linaclotide - rifaximin - asimadoline - dexloxiglumide - eluxadoline - rifaximin - tenapanor - linaclotide - plecanatide - solabegron hydrochloride - elobixibat - ONO-2952 - LX-1033 - ASP-7147 - (mosapride Bacillus subtilis Streptococcas feacium) - DSP-6952 - SKI-3246 - SYN-010 - linaclotide - larazotide acetate - DA-6886 - YH-12852 - mexiletine hydrochloride - MDT-006 - RQ-00202730 - PBI-1737 - RQ-00310941 - GIC-1001 For more information visit http://www.researchandmarkets.com/research/tq...able_bowel
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2014 Healthcare Conference
Business Wire - Wed May 07, 7:30AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present a corporate update at the Bank of America Merrill Lynch 2014 Healthcare Conference on Tuesday, May 13, 2014 at 3:40 p.m. Pacific Time/6:40 p.m. Eastern Time at the Encore at the Wynn in Las Vegas, NV.
Positive Data, Financial Results, and Drug Development Programs - Analyst Notes on Novavax, Ironwood, XOMA, Luminex and Amicus
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Novavax, Inc. (NASDAQ: NVAX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), XOMA Corporation (NASDAQ: XOMA), Luminex Corporation (NASDAQ: LMNX) and Amicus Therapeutics, Inc. (NASDAQ: FOLD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1940-100free.
Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week(R) 2014
Business Wire - Thu May 01, 7:31AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today they will present linaclotide-related data during Digestive Disease Week(R) 2014 in Chicago, May 3 through May 6, 2014. The data will be presented through the following poster presentations:
Ironwood Up as Loss Narrows, Linzess Shines - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:45PM CDT
Ironwood Pharmaceuticals, Inc. (IRWD) reported a loss of 38 cents per share in the first quarter of 2014.
Why Ironwood Pharmaceuticals Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 29, 1:11PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Ironwood Pharmaceuticals , a...
Why Ironwood Pharmaceuticals (IRWD) Stock Is Soaring Today
at The Street - Tue Apr 29, 9:33AM CDT
Ironwood Pharmaceuticals (IRWD) is up double digits after beating analysts first quarter revenue estimates by 71%
Upcoming Earnings Release Dates -- Research on HudsonCity Bancorp, 3D Systems, Ironwood Pharma, and Archer-Daniels-Midland
PR Newswire - Tue Apr 29, 7:50AM CDT
Earningsource.com provides investors with earnings schedule updates throughout the earnings season. With timely information on past earnings performance and earnings projection for their upcoming quarterly release, our aim is to ensure shareholders and traders have an edge on their investment decisions on the following companies: Hudson City Bancorp Inc. (NASDAQ: HCBK), 3D Systems Corp. (NYSE: DDD), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) and Archer-Daniels-Midland Co. (NYSE: ADM). Full earnings notes on HCBK, DDD, IRWD and ADM can be downloaded upon signing up at:
Ironwood Pharmaceuticals Provides First Quarter 2014 Investor Update
Business Wire - Tue Apr 29, 6:05AM CDT
--- Multi-channel Direct-to-Consumer awareness campaign launched -
Valeant Eyes Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 4:40PM CDT
Shares of Allergan (AGN) gained 15.2% after Valeant Pharmaceuticals International, Inc. (VRX) and Pershing Square Capital Management, L.P made a formal proposal to acquire the former.
Upcoming Conference Calls, Commencement of Shipments, Stock Price Movements, Awareness Campaigns, and Acquisitions - Analyst Notes on Incyte, Impax, ANI, Ironwood and Aastrom
PR Newswire - Thu Apr 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), Impax Laboratories Inc. (NASDAQ: IPXL), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) and Aastrom Biosciences, Inc. (NASDAQ: ASTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1519-100free.
Why Ironwood Pharmaceuticals (IRWD) is Poised to Beat Earnings Estimates (Again) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 7:56AM CDT
Recent estimates have been moving higher for Ironwood Pharmaceuticals which is a great sign of a coming beat.
Ironwood Pharmaceuticals and Forest Laboratories announce new LINZESS campaign
M2 - Fri Apr 11, 7:26AM CDT
US-based medicinal company Ironwood Pharmaceuticals (NasdaqGS:IRWD) and US-based Forest Laboratories (NYSE:FRX) launched on Thursday a new direct-to-consumer (DTC) patient awareness campaign for LINZESS (linaclotide) for treating adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Ironwood and Forest Launch New Direct-to-Consumer Awareness Campaign For LINZESS(R)
Business Wire - Thu Apr 10, 7:30AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today that they have commenced a new direct-to-consumer (DTC) patient awareness campaign for LINZESS(R) (linaclotide), a once-daily treatment for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). The campaign aims to help adults suffering from IBS-C or CIC recognize the symptoms of these disorders, describe their symptoms to their doctor, and ask their doctor about LINZESS to help proactively manage their disease. The television portion of the campaign premiered last night on ABC.
Ironwood Pharmaceuticals to Host First Quarter 2014 Investor Update Call
Business Wire - Tue Apr 08, 6:00AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its first quarter 2014 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, April 29, 2014. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 3733415. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
Ironwood Initiates GERD Study, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:25PM CDT
Ironwood Pharmaceuticals announced the initiation of a phase IIa study on its gastroesophageal reflux disease candidate, IW-3718.
Use Options For A Chance To Buy IRWD At A 31% Discount
at The Street - Wed Mar 19, 10:42AM CDT
Looking back to 36 days ago, Ironwood Pharmaceuticals Inc. priced a 13,725,500 share secondary stock offering at $12.75 per share.
Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease
Business Wire - Tue Mar 18, 7:00AM CDT
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in its Phase IIa clinical study of its investigational compound IW-3718 in patients suffering from gastroesophageal reflux disease (GERD) who have not responded adequately to treatment with a proton pump inhibitor (PPI). Data are expected in the first half of 2015.
